ReviewNature reviews. Drug discovery2010
TNF receptor 2 pathway: drug target for autoimmune diseases.
Review in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 249 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
249 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of whole-body vibration training on inflammatory markers and lipid profiles in adults: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- Paneth Cells: Recent Updates on Elucidating Therapeutic Implications in Gastroenterological Disease Management.Current medicinal chemistry · 2025Pooled it
- Trial
- Late TNFα blockade is associated with systemic immune rewiring without disease control in established experimental autoimmune hepatitis.Journal of translational autoimmunity · 2026Article
- Myeloid cell reprogramming drives enhanced defense againstProceedings of the National Academy of Sciences of the United States of America · 2026Article
- TNFR Pathway-Related Proteins and Recurrent Coronary Artery Disease Events.JACC. Advances · 2026Article
- Influence of Different Death Receptor Signaling Pathways on Apoptosis ofCurrent issues in molecular biology · 2026Article
- Decoding Treg diversity and dysfunction to advance Treg-based therapies in autoimmune and inflammatory diseases.Frontiers in immunology · 2026Review
- Serum BAFF, APRIL, TWEAK, TNFSF18, TNFR2, and TNFRS12A levels in preschool children with autism spectrum disorder.International journal of developmental disabilities · 2026Article
- Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistance.Frontiers in immunology · 2026Review
- TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases.International journal of molecular sciences · 2025Review
- Molecular mechanisms and complications of TNF blockade in heart failure: targeting signalling and genetic determinants of therapeutic response.Molecular biology reports · 2025Review
- Endothelial cell source dictates the expression and release of fibrinolytic markers in a proinflammatory environment.Research and practice in thrombosis and haemostasis · 2025Article
- Restorative Effects of Synbiotics on Colonic Ultrastructure and Oxidative Stress in Dogs with Chronic Enteropathy.Antioxidants (Basel, Switzerland) · 2025Article
- Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis.Scientific reports · 2025Article
- Role of Tumor Necrosis Factor in Tuberculosis.Biomolecules · 2025Review
- Unexpectedly High and Difficult-to-Explain Regenerative Capacity in an 82-Year-Old Patient with Insulin-Requiring Type 2 Diabetes and End-Stage Renal Disease.Journal of clinical medicine · 2025Article
- Splenic TNF-α signaling potentiates the innate-to-adaptive transition of antiviral NK cells.Immunity · 2025Article
- Multi-omics delineate growth factor network underlying exercise effects in an Alzheimer's mouse model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Neurotrophomodulatory effect of TNF-α through NF-κB in rat cortical astrocytes.Cytotechnology · 2025Review
189 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.
Indexed as
Identifiers
20489699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.